Latest Product Launches News

Harmoney Corp Limited reported a staggering 742% increase in Cash NPAT for FY25, driven by its new Stellare® 2.0 platform and operational efficiencies. The company reaffirmed its ambitious $12 million profit target for FY26 while unveiling a secured car loan product and securing a major bank debt facility.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

McPherson’s Limited has unveiled a sweeping two-year transformation, streamlining its brand portfolio and adopting a scalable third-party logistics model to drive growth and improve financial stability.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Ava Risk Group’s BQT Solutions has inked a five-year supply and co-development agreement with US-based UniKey Technologies, targeting the booming mobile credential access market with new NFC/BLE readers.

Collins Foods Limited has reported record half-year revenues of $750.3 million, with underlying net profit after tax surging 29.5%. The company’s operational improvements and expansion in Europe underpin an upgraded FY26 outlook.

VEEM Limited reported a year of consolidation in FY25 with solid second-half growth driven by new defence contracts and the promising launch of its VEEM Extreme propulsion system. Despite a revenue dip, the company is poised for a stronger FY26 backed by strategic US defence partnerships and product innovation.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Integrated Research Limited reported a modest revenue dip and significant profit declines in FY25 as it pivots to a product-led growth strategy focused on AI-powered observability solutions and hybrid pricing models.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.